1. HBW Insight
  2. >>Leadership

Moeller Takes P&G Reins With 33-Year Grasp Of Products, Planning And Footprint

 
• By Eileen Francis

Jon Moeller appointed to succeed David Taylor, at the helm for almost six years and remaining as executive chairman, a day before P&G releases FY21 full-year and Q4 results.

Cincinnati - Circa May 2017: Wide Angle Procter & Gamble Corporate Headquarters. P&G is an American Multinational Consumer Goods Company VII

Jon Moeller’s 33-year climb up Procter & Gamble Co.’s corporate ladder reached the summit with his promotion from vice chairman and chief operating officer to president and CEO.

Taking the reins from David Taylor, who was at the helm for almost six years and will continue as executive chairman, Moeller’s tenure comes with the firm returned to “consistent balanced growth and value creation,” said James McNerney, lead director of P&G’s board in an

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By David Ridley

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.

Makary’s Reorganization Decision A Turning Point For US FDA?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

US FDA Retirements Continue Unabated With Drug Inspectorate Leaders, Former Chief Counsel

 
• By Sue Sutter and Derrick Gingery

Alonza Cruse, director of the Office of Human and Animal Drugs Inspectorate, and two other senior inspection officials are departing, along with Mark Raza, chief counsel from 2021 until January.

More from HBW Insight

Coty Lowers FY25 Forecast On Tariff Uncertainty, Inventory Reductions, But Expects Sunnier Days In FY26

 
• By Eileen Francis

Coty lowers its revenue and profit outlook for FY25, though it believes FY26 will be a better year thanks to a return of ‘blockbuster’ product launches, market expansion and mitigation strategies for current economic uncertainties.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By David Ridley

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”